STERIS plc provides infection prevention and other procedural products and services worldwide.
$264.32+4.29%
报价 2026-11-13
市值
$25.67B
EV
$26.4B
PE (TTM)
30.3x
预期 PE (FY2027)
23.2x
52 周区间距高点 -1.6%
$199.40$268.65
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Medical - Devices| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| STESTERIS plc | $25.67B | +4.3% | +7.3% | 44.7% | 30.3x | 17.2x | 26.6x | |
| EWEdwards Lifesciences Corporation | $61.61B | +1.3% | +12.7% | 78.1% | 44.5x | 32.6x | 43.3x | GARP |
| DXCMDexCom, Inc. | $31.08B | +2.4% | +12.4% | 63.4% | 34.4x | 21.8x | 23.9x | GARP |
| PHGKoninklijke Philips N.V. | $29.47B | +1.0% | – | 45.2% | 24.5x | 10.1x | – | |
| ZBHZimmer Biomet Holdings, Inc. | $19.53B | -1.3% | +4.9% | 71.2% | 27.1x | 12.0x | 12.3x | |
| GKOSGlaukos Corporation | $14.55B | -0.1% | +56.0% | 85.2% | – | – | 392.4x | 高增长 |
| SNNSmith & Nephew plc | $13.09B | +0.9% | – | 68% | 22.0x | 10.3x | – | |
| PENPenumbra, Inc. | $12.65B | +0.0% | +15.9% | 67.1% | 74.0x | 59.0x | 63.1x | |
| ALGNAlign Technology, Inc. | $11.86B | +0.8% | +2.6% | 68.7% | 25.0x | 14.9x | 20.1x | |
| 同行中位数 | – | – | +12.6% | 68.4% | 27.1x | 14.9x | 33.6x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-09-30 Q2 2027 | 2026-06-30 Q1 2027 | 2026-03-31 Q4 2026 | 2025-12-31 Q3 2026 | 2025-09-30 Q2 2026 | 2025-06-30 Q1 2026 | 2025-03-31 Q4 2025 | 2024-12-31 Q3 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.59B | $1.49B | $1.59B | $1.5B | $1.46B | $1.39B | $1.48B | $1.37B |
| Gross Margin | 44.7% | 45.8% | 43.9% | 43.8% | 44.2% | 45.1% | 43.3% | 44.5% |
| Operating Margin | 18.5% | 19.1% | 19.9% | 18.1% | 18.4% | 17.7% | 14.6% | 17.9% |
| Net Income | $213.7M | $200.1M | $220.3M | $192.8M | $191.9M | $177.4M | $145.7M | $173.5M |
| Diluted EPS | 2.19 | 2.04 | 2.24 | 1.96 | 1.94 | 1.79 | 1.48 | 1.75 |
| Operating Cash Flow | $288.8M | $367.1M | $335.4M | $298.2M | $287.8M | $420M | $260.8M | $332.8M |